Ginkgo Bioworks Holdings, Inc. (DNABW) — SEC Filings
Ginkgo Bioworks Holdings, Inc. (DNABW) — 35 SEC filings. Latest: 8-K (Dec 23, 2025). Includes 13 8-K, 8 SC 13G/A, 6 10-Q.
View Ginkgo Bioworks Holdings, Inc. on SEC EDGAR
Overview
Ginkgo Bioworks Holdings, Inc. (DNABW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 6, 2025: Ginkgo Bioworks Holdings, Inc. filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. Ginkgo Bioworks, previously known as Soaring Eagle Acquisition Corp. and Spinning Eagle Acquisition Corp., is i
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 2 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Ginkgo Bioworks Holdings, Inc. is neutral.
Filing Type Overview
Ginkgo Bioworks Holdings, Inc. (DNABW) has filed 13 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 8 SC 13G/A, 1 DEFA14A, 1 8-K/A, 1 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of DNABW's 22 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $136,759,000 |
| Net Income | -$232,012,000 |
| Cash Position | $111,065,000 |
| Total Assets | $1,189,165,000 |
Key Executives
- Kelly Jason R
Industry Context
Ginkgo Bioworks operates in the rapidly evolving synthetic biology sector, aiming to make biology easier to engineer for customers across various industries. The competitive landscape includes other synthetic biology platforms, contract research organizations (CROs), and internal R&D efforts by large pharmaceutical, agricultural, and chemical companies. Key industry trends involve increasing demand for sustainable solutions, advancements in gene editing technologies, and the growing application of biological engineering in areas like therapeutics, agriculture, and materials science.
Top Tags
sec-filing (5) · biotechnology (5) · Biotechnology (4) · corporate-governance (4) · amendment (4) · corporate-actions (3) · 10-Q (3) · financials (3) · Synthetic Biology (2) · Revenue Decline (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $136.759M | 25.3% decrease from $183.196 million in 2024 |
| Net Loss | $232.012M | Widened from $439.495 million in 2024 (which included goodwill impairment) |
| Cash and Cash Equivalents | $111.065M | Significant decrease from $561.572 million at December 31, 2024 |
| Cell Engineering Revenue | $106.744M | 23.3% decrease from $139.183 million in 2024 |
| Biosecurity Revenue | $30.015M | 31.8% decrease from $44.013 million in 2024 |
| Total Operating Expenses | $381.285M | 40.4% decrease from $639.347 million in 2024 |
| Research and Development Expenses | $193.646M | 44.3% decrease from $347.684 million in 2024 |
| General and Administrative Expenses | $137.276M | 27.3% decrease from $188.864 million in 2024 |
| Purchases of Marketable Debt Securities | $401.838M | Major cash outflow in investing activities |
| Class A common stock shares outstanding | 48,523,595 | As of October 31, 2025 |
| Cell Engineering Revenue (Q2 2025) | $12.5M | Increased from $10.2M in Q2 2024, showing 22.5% growth. |
| Total Revenue (Q2 2025) | $45.0M | Decreased from $55.0M in Q2 2024, a 18.2% decline. |
| Biosecurity Revenue (Q2 2025) | $32.5M | Decreased from $44.8M in Q2 2024, a 27.4% decline. |
| New Cell Engineering Programs | 25 | Added in the first half of 2025, indicating platform expansion. |
| Total Revenue (H1 2025) | $90.0M | Down from $110.0M in H1 2024, a 18.2% decline year-over-year. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ginkgo Bioworks Holdings, Inc. (DNABW)?
Ginkgo Bioworks Holdings, Inc. has 35 recent SEC filings from Jan 2024 to Dec 2025, including 13 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DNABW filings?
Across 35 filings, the sentiment breakdown is: 2 bearish, 32 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Ginkgo Bioworks Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ginkgo Bioworks Holdings, Inc. (DNABW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ginkgo Bioworks Holdings, Inc.?
Key financial highlights from Ginkgo Bioworks Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DNABW?
The investment thesis for DNABW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ginkgo Bioworks Holdings, Inc.?
Key executives identified across Ginkgo Bioworks Holdings, Inc.'s filings include Kelly Jason R.
What are the main risk factors for Ginkgo Bioworks Holdings, Inc. stock?
Of DNABW's 22 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Ginkgo Bioworks Holdings, Inc.?
Forward guidance and predictions for Ginkgo Bioworks Holdings, Inc. are extracted from SEC filings as they are enriched.